AIM ImmunoTech Inc (AMEX: AIM)’s stock price has dropped by -13.74 in relation to previous closing price of 0.56. Nevertheless, the company has seen a loss of -0.82% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-02 that AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2023 Earnings Conference Call April 2, 2024 8:30 AM ET Company Participants Thomas Equels – Chief Executive Officer Dr. Christopher McAleer – Scientific Officer Conference Call Participants James Molloy – Alliance Global Partners Ed Woo – Ascendiant Capital Markets Operator Hello. And welcome to the AIM ImmunoTech Fiscal Year 2023 Update Conference Call and Webcast.
Is It Worth Investing in AIM ImmunoTech Inc (AMEX: AIM) Right Now?
Additionally, the 36-month beta value for AIM is -0.19. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AIM is 45.32M and currently, short sellers hold a 1.09% ratio of that float. The average trading volume of AIM on April 16, 2024 was 226.74K shares.
AIM’s Market Performance
AIM’s stock has seen a -0.82% decrease for the week, with a 45.37% rise in the past month and a 7.21% gain in the past quarter. The volatility ratio for the week is 13.50%, and the volatility levels for the past 30 days are at 12.65% for AIM ImmunoTech Inc The simple moving average for the past 20 days is 4.45% for AIM’s stock, with a -3.63% simple moving average for the past 200 days.
AIM Trading at 13.92% from the 50-Day Moving Average
After a stumble in the market that brought AIM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.25% of loss for the given period.
Volatility was left at 12.65%, however, over the last 30 days, the volatility rate increased by 13.50%, as shares surge +46.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.45% upper at present.
During the last 5 trading sessions, AIM fell by -0.82%, which changed the moving average for the period of 200-days by -17.83% in comparison to the 20-day moving average, which settled at $0.4719. In addition, AIM ImmunoTech Inc saw 10.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AIM starting from BRYAN NANCY, who purchase 38,462 shares at the price of $0.39 back on Mar 21 ’24. After this action, BRYAN NANCY now owns 38,462 shares of AIM ImmunoTech Inc, valued at $15,000 using the latest closing price.
APPELROUTH STEWART, the Director of AIM ImmunoTech Inc, purchase 90,910 shares at $0.33 during a trade that took place back on Mar 15 ’24, which means that APPELROUTH STEWART is holding 239,765 shares at $30,000 based on the most recent closing price.
Stock Fundamentals for AIM
Current profitability levels for the company are sitting at:
- -156.25 for the present operating margin
- -0.36 for the gross margin
The net margin for AIM ImmunoTech Inc stands at -139.35. The total capital return value is set at -2.93. Equity return is now at value -118.94, with -64.84 for asset returns.
Based on AIM ImmunoTech Inc (AIM), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -95.37. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 49.78.
Currently, EBITDA for the company is -31.66 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 96.39. The receivables turnover for the company is 0.17for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.68.
Conclusion
In conclusion, AIM ImmunoTech Inc (AIM) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
